Document Detail


The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy.
MedLine Citation:
PMID:  22189841     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Renin-angiotensin-aldosterone system inhibitors prevent the progression of kidney disease in patients with diabetic nephropathy, and we studied how that benefit varies by the type of diabetes and baseline urinary albumin. We pooled data from 49 randomized controlled trials in a meta-analysis using the ratio of endpoint urinary albumin levels in those treated compared to those untreated with renin-angiotensin-aldosterone system inhibitors in both fixed- and random-effects models. The urinary albumin excretion for treated microalbuminuric patients with Type 1 diabetes was on average 60% lower at the end of the trial compared with patients not treated with renin-angiotensin-aldosterone system inhibitors using the fixed-effects model and 67% lower using the random-effects model. There was no significant effect of treatment in patients with normal albumin excretion. For normoalbuminuric patients with Type 2 diabetes, urinary albumin excretion was on average 12% lower after treatment using the fixed-effects model compared to 21% lower using the random-effects model. For microalbuminuric patients, urinary albumin excretion was on average 23% lower using the fixed-effects model and 27% lower using the random-effects model. Thus, renin-angiotensin-aldosterone system inhibition reduced urinary albumin excretion for Type 1 diabetic patients with micro-, but not those with normoalbuminuria. Treatment reduced urinary albumin excretion for Type 2 diabetic patients with and without microalbuminuria.
Authors:
Jennifer A Hirst; Kathryn S Taylor; Richard J Stevens; Claire L Blacklock; Nia W Roberts; Christopher W Pugh; Andrew J Farmer
Publication Detail:
Type:  Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't     Date:  2011-12-21
Journal Detail:
Title:  Kidney international     Volume:  81     ISSN:  1523-1755     ISO Abbreviation:  Kidney Int.     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-15     Completed Date:  2012-07-16     Revised Date:  2014-06-20    
Medline Journal Info:
Nlm Unique ID:  0323470     Medline TA:  Kidney Int     Country:  United States    
Other Details:
Languages:  eng     Pagination:  674-83     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Albuminuria / drug therapy,  physiopathology
Angiotensin Receptor Antagonists / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Diabetes Mellitus, Type 1 / drug therapy*,  physiopathology
Diabetes Mellitus, Type 2 / drug therapy*,  physiopathology
Diabetic Nephropathies / drug therapy*,  physiopathology
Disease Progression
Female
Humans
Male
Models, Biological
Randomized Controlled Trials as Topic
Regression Analysis
Renin-Angiotensin System / drug effects*
Grant Support
ID/Acronym/Agency:
08/67/03//Department of Health; HTA/08/67/03//Department of Health
Chemical
Reg. No./Substance:
0/Angiotensin Receptor Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors
Comments/Corrections
Comment In:
Kidney Int. 2012 Apr;81(7):615-6   [PMID:  22419043 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Genotype-based changes in serum uric acid affect blood pressure.
Next Document:  The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligi...